• linkedin
  • Increase Font
  • Sharebar

    How kidney Ca management strategies compare



    In an evaluation of circulating “cell-free” tumor DNA (liquid biopsy) and known mutations found in RCC, researchers determined that 67% of their cohort had detectable DNA mutations versus 3% of control patients. They were able to detect RCC in patients with both early and advanced stages and were able to detect RCC in a tumor as small as 1.1 cm.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available